CCND1
G1/S-specific cyclin-D1
As of the edition of 20 October 2026, CCND1 (G1/S-specific cyclin-D1, UniProt P24385) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P24385
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 11
- Disease areas
- Blood and lymph; Cancer; Immune system; Digestive system; Skin and connective tissue; Hormones; Inherited and neonatal; Heart and blood vessels
- Registered trials of its drugs
- 38
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Rigosertib | Stopped | Phase 3 | none listed |
| Briciclib | Stopped | Phase 1 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Traws Pharma | Route A |
| SymBio Pharmaceuticals | Route A |
The other 0 companies at CCND1
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at CCND1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.